Core Insights - The core message of the news is that Jiashitang Pharmaceutical Co., Ltd. has successfully obtained dual certification for its compliance management system, marking a significant milestone in its development and demonstrating its commitment to compliance and internal control [2][3]. Group 1: Certification Achievement - Jiashitang has received a compliance management system certification, highlighting its excellence in compliance management and internal control [2]. - The certification reflects Jiashitang's responsibility as a state-owned enterprise and its determination for continuous self-reform [2]. Group 2: Compliance Management Philosophy - The company emphasizes that compliance is the foundation for sustainable development and a source of value creation [2]. - Jiashitang aims to deepen its compliance management system, integrating it with operational management to support business expansion, risk prevention, and brand enhancement [2]. Group 3: Political Responsibility and Industry Self-Regulation - The dual certification is seen as a milestone event that aligns with the central government's regulations and the commitment to strict governance [3]. - Jiashitang demonstrates a strong belief in building a compliance system and maintains a zero-tolerance policy towards violations [3].

Market Overview - The pharmaceutical commercial sector increased by 1.04% on July 30, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3615.72, up 0.17%, while the Shenzhen Component Index closed at 11203.03, down 0.77% [1] Top Performers - Huaren Health (301408) closed at 15.01, up 5.48% with a trading volume of 334,100 shares and a transaction value of 499 million [1] - Jiazhang Tang (002462) closed at 14.67, up 4.19% with a trading volume of 232,300 shares and a transaction value of 346 million [1] - Laobaixing (603883) closed at 19.69, up 2.93% with a trading volume of 398,800 shares and a transaction value of 779 million [1] - China National Pharmaceutical (600056) closed at 11.28, up 2.64% with a trading volume of 656,900 shares and a transaction value of 747 million [1] Underperformers - Renmin Tongtai (600829) closed at 8.77, down 7.20% with a trading volume of 724,400 shares and a transaction value of 651 million [2] - Saily Medical (603716) closed at 30.89, down 2.31% with a trading volume of 444,300 shares and a transaction value of 1.385 billion [2] - Runda Medical (603108) closed at 18.20, down 1.83% with a trading volume of 299,700 shares and a transaction value of 552 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 62.07 million from institutional investors, while retail investors saw a net inflow of 64.93 million [2] - Major stocks like Laobaixing and China National Pharmaceutical had significant net inflows from retail investors, despite overall sector outflows [3] Individual Stock Analysis - Laobaixing (603883) had a net inflow of 62.57 million from institutional investors, but a net outflow of 45.34 million from retail investors [3] - China National Pharmaceutical (600056) saw a net inflow of 49.86 million from institutional investors, with a net outflow of 43.44 million from retail investors [3] - Huaren Health (301408) had a net inflow of 21.02 million from institutional investors, but a net outflow of 26.49 million from retail investors [3]

Group 1 - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a 5-year lifecycle, starting mass production in Q2 2026 [1] - Zhongke Environmental reported a net profit of 196 million yuan for the first half of 2025, a year-on-year increase of 19.83%, with revenue of 848 million yuan, up 4.48% [1] - WuXi AppTec's net profit for the first half of 2025 grew by 101.92% to 8.561 billion yuan, with revenue of 20.799 billion yuan, a 20.64% increase [1][2] - Sujiao Technology's net profit decreased by 39.54% to 95.39 million yuan, with revenue down 13.75% to 1.776 billion yuan [1] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5%, with revenue of 575 million yuan, up 11.69% [1] Group 2 - Sanxiang New Materials plans to invest up to 300 million yuan in a zirconium-hafnium separation project, with a production capacity of 20,000 tons [1] - Koweil received government subsidies totaling 4.9752 million yuan, accounting for 10.14% of its audited net profit [1] - Xinhua Medical obtained two Class II medical device registration certificates for digital X-ray machines [1] - Huanxu Electronics reported a net profit of 638 million yuan, down 18.66%, with total revenue of 27.214 billion yuan, a slight decrease of 0.63% [1] - Zhenhua Co.'s general manager was fined 100,000 yuan for violations related to stock trading by his child [1] Group 3 - Huafeng Aluminum signed a raw material purchase contract worth over 7.2 billion yuan for a five-year period, committing to purchase at least 360,000 tons of raw materials [1] - Hongxin Technology received a project designation letter and procurement contract from a major domestic automotive brand [1] - Meihe Co. obtained a patent for a device used in supporting automatic flipping on conveyor lines in the automotive manufacturing sector [1] - Xin Hongye's subsidiary won a bid for an electrical penetration project worth 40.8831 million yuan [1] - Fuan Pharmaceutical's subsidiary received a drug registration certificate for an injection used in liver disease treatment [1] Group 4 - Tianzhong Precision's subsidiary's bankruptcy liquidation application was accepted by the court due to insufficient assets to cover debts [1] - Zhonghong Medical's subsidiary received medical device registration for infusion pumps and information collection systems [1] - Keda Li's subsidiary completed a capital increase, raising its registered capital from 200 million yuan to 400 million yuan [1] - Xingye Technology applied for a credit limit of 372 million yuan from Guangfa Bank [1] - Hengrui Medicine signed a collaboration agreement with GSK, involving a potential total payment of approximately 12 billion USD based on project milestones [1]

证券代码：002462 证券简称：嘉事堂 公告编号：2025-29 嘉事堂药业股份有限公司 关于取得合规管理体系认证证书的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 三、备查文件 《合规管理体系认证证书》（证书编号：00625CMS20005ROM） 特此公告。 嘉事堂药业股份有限公司董事会 2025 年 7 月 28 日 一、基本情况 嘉事堂药业股份有限公司（以下简称"公司"）近日取得由中质协质量保证 中心颁发的《合规管理体系认证证书》（证书编号：00625CMS20005ROM），兹证 明公司合规管理体系符合 GB/T35770-2022 及 ISO37301:2021 标准。 认证范围：集团总部与药品销售（药品经营许可证范围内）、医疗器械（医 疗器械经营许可证内、医疗器械经营备案凭证内)、医药仓储物流管控有关的合 规管理。 二、对公司的影响 本次获得合规管理体系认证证书，标志着公司合规管理水平已全面接轨国际 标准，证明嘉事堂始终践行"人人讲合规，事事讲合规，时时讲合规，合规创造 价值"的合规理念，持续深耕合规管理体系建设。通过推动 ...

Core Points - The internal audit regulations of Jiasitang Pharmaceutical Co., Ltd. aim to enhance the quality of internal audit work and ensure compliance with relevant laws and regulations [1][2] - The internal audit department is responsible for independent supervision, evaluation, and recommendations regarding the company's operations, financial management, risk management, and internal controls [1][4] Group 1: General Principles - The internal audit work is guided by Xi Jinping's thoughts on socialism with Chinese characteristics and focuses on economic supervision, financial legality, and effectiveness [1][2] - The internal audit department must maintain integrity, objectivity, and independence while avoiding conflicts of interest [2][3] Group 2: Internal Audit Structure - The company has established an internal audit department that reports directly to the board of directors and the audit committee [2][3] - The board of directors is responsible for approving the basic audit system and the annual audit project plan [3][4] Group 3: Responsibilities and Authority - The internal audit department is tasked with auditing the economic responsibilities of management, compliance with national policies, financial management, and internal controls [4][5] - The department has the authority to inspect relevant documents, attend meetings, and report significant issues to the board and the party committee [5][6] Group 4: Audit Types and Procedures - Internal audit activities include economic responsibility audits, routine audits, special audits, and audit research [6][7] - The internal audit department must ensure comprehensive coverage of subsidiaries and adhere to a risk-oriented approach in planning audits [7][8] Group 5: Management and Quality Control - The internal audit department is responsible for managing audit quality and ensuring compliance with established standards [9][10] - The department must not outsource its core functions but may engage third parties for specific audit tasks under supervision [9][10] Group 6: Utilization of Audit Results - The company should establish mechanisms for addressing audit findings and ensuring accountability for corrective actions [10][11] - Audit results are to be used as a reference for evaluating management performance and making personnel decisions [10][11] Group 7: Assessment and Accountability - The company will implement an incentive and accountability mechanism for the internal audit department and its personnel [11][12] - Internal audit personnel may be held accountable for failing to comply with regulations or for misconduct [11][12]

Core Points - The document outlines the responsibilities and authority of the president of Jia Shitang Pharmaceutical Co., Ltd, aiming to enhance corporate governance and ensure scientific decision-making [1][2][3] - The president is accountable to the board of directors and is responsible for the company's operational management, including implementing board resolutions and reporting on work progress [1][2][3] - The document specifies the limits of the president's decision-making authority, particularly regarding financial transactions and investments, which are capped at 10% of the company's audited net assets for various activities [3][4] Section Summaries General Provisions - The document establishes guidelines for the president's duties and the governance structure of the company, ensuring compliance with relevant laws and regulations [1][2] Authority of the President - The president has the authority to manage daily operations, propose board meeting agendas, and make decisions on various operational matters within the scope defined by the board [2][3] - Specific financial thresholds for transactions and investments are set, including limits for related party transactions and external investments [3][4] Responsibilities and Obligations - The president must adhere to the company's articles of association and board resolutions, ensuring the integrity and confidentiality of company information [6][12] - Regular reporting to the board is mandated, including updates on significant contracts, financial performance, and major investment projects [11][12] Meeting Procedures - The document outlines the procedures for the president's office meetings, including the requirement for a quorum and the process for decision-making [20][26] - It emphasizes the importance of collective decision-making and the need for transparency in discussions related to significant company matters [27][28] Reporting System - The president is required to provide regular and ad-hoc reports to the board, ensuring accountability and transparency in the company's operations [31][32] - The document mandates that all reports must be accurate and complete, reflecting the true state of the company's affairs [12][34] Miscellaneous Provisions - The document states that any previous regulations are nullified upon the adoption of this new guideline, ensuring a clear and updated governance framework [13]

嘉事堂药业股份有限公司 总裁工作细则 第一章 总则 第一条 为进一步完善嘉事堂药业股份有限公司（以下 简称"公司"）法人治理结构，明确总裁的职责，规范总裁 及其他高级管理人员工作行为，确保公司经营决策的科学性、 合理性、规范性，根据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司治理准则》等有关法律法规和 规范性文件以及《嘉事堂药业股份有限公司章程》（以下简 称"《公司章程》"）规定，结合公司实际情况，制定本细 则。 第二条 公司总裁及其他高级管理人员由董事会聘任或 解任，组成公司经营班子，行使《公司章程》和董事会赋予 的职权，组织实施决议，对董事会负责和汇报工作。 第二章 总裁及其他高级管理人员的职权 第三条 总裁对董事会负责，依据《公司章程》及董事 会的授权范围，行使下列职权： （一）主持公司的生产经营管理工作，组织实施董事会决 议，并向董事会报告工作； （二）提出董事会议案； （三）拟订公司内部管理机构设置方案； （四）拟订公司的基本管理制度； 第 1 页 共 10 页 （五）制定公司的具体规章； （十四）在董事会授权范围内，决定公司对外投资、收购 或出售资产、资产抵押、对外担保事项、委托理 ...

嘉事堂药业股份有限公司 内部审计基本规定 （2025 年修订） 第一章 总 则 第一条 为加强党对审计工作的集中统一领导，充分发 挥嘉事堂药业股份有限公司（以下简称"公司"）审计监督作 用，提高内部审计工作质量，根据《中华人民共和国审计法》 《审计署关于内部审计工作的规定》《中国内部审计准则》等 法律法规，以及《中国光大集团股份公司内部审计基本规定》、 《公司章程》，结合公司实际情况，制定本规定。 第二条 公司内部审计工作以习近平新时代中国特色社 会主义思想为指导，认真落实党中央经济方针政策和集团战 略决策部署，坚持立足经济监督定位，聚焦财务收支真实合 法效益主责主业，深化研究型审计，聚焦全局性、长远性、 战略性问题，构建集中统一、全面覆盖、权威高效的审计监 督体系，进一步推进审计工作高质量发展。 第三条 内部审计是公司内部独立、客观的监督、评价和 建议活动，运用系统化、规范化方法，审查评价并督促改善 公司全辖各企业业务经营、财务收支、风险管理、内部控制 和公司治理效果，促进公司稳健运行，实现战略目标。 第四条 内部审计部门应当践行诚实守信、以义取利、稳 健审慎、守正创新、依法合规的中国特色金融文化，打造忠 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-28 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 嘉事堂药业股份有限公司（以下简称"公司"）2025 年 7 月 25 日召开的第 七届董事会第十七次临时会议审议通过了《关于修订<嘉事堂药业股份有限公司 内部审计基本制度>的议案》，根据《中华人民共和国审计法》《审计署关于内部 审计工作的规定》《中国内部审计准则》《深圳证券交易所上市公司自律监管指引 第 1 号主板上市公司规范运作》等相关法律法规的要求，并结合公司业务发展需 要等实际情况，嘉事堂对《嘉事堂药业股份有限公司内部审计基本制度》（以下 简称"《内审制度》"）进行修改。 本次《内审制度》新增 13 条，删除 6 条，修订 17 条。主要修改内容为： 1、新增党对内审工作的领导； 7、新增审计结果运用章节。 具体《内审制度》修订内容详见附件。 特此公告。 附件：《嘉事堂药业股份有限公司内部审计基本制度》修订对比说明 嘉事堂药业股份有限公司董事会 嘉事堂药业股份有限公司 关于修订《内部审计基本制度》的公告 2025 年 7 月 26 日 2、 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-27 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 嘉事堂药业股份有限公司（以下简称"公司""本公司"）第七届董事会第十 七次临时会议于 2025 年 7 月 14 日以电子邮件的方式发出会议通知。会议于 2025 年 7 月 25 日以通讯表决的方式召开。会议应表决的董事 9 名，实际表决的董事 9 名。本次会议的召开及表决程序符合《公司法》《公司章程》及《董事会议事规 则》的有关规定。 二、董事会会议审议情况 1、关于制订《嘉事堂药业股份有限公司总裁工作细则》的议案 同意 9 票，反对 0 票，弃权 0 票，议案获得通过。 为进一步完善嘉事堂药业股份有限公司法人治理结构，明确总裁的职责，规 范总裁及其他高级管理人员工作行为，确保公司经营决策的科学性、合理性、规 范性，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》等有关法律法规和规范性文件以及《嘉事堂药业股份有限公司章程》规定， 结合公司实际情况，公司制订《嘉事堂药业股份有限公司总裁工作细则》 ...